Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.63 |
| ▸ | JAK2 | O60674 | 3/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.56 |
| ▸ | FLT3 | P36888 | 3/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.56 |
| ▸ | CLK2 | P49760 | 2/20 | 0.56 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.56 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.56 |
| ▸ | FER | P16591 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | MARK3 | P27448 | 1/20 | 0.56 |
| ▸ | FLT4 | P35916 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32382061 | 1.00 | PDPK1 (0.63) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL15288061 | 0.84 | PDPK1 (0.63) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL29502104 | 0.84 | PDPK1 (0.63) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL30855645 | 0.79 | PDPK1 (0.68) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL14095607 | 0.79 | ITK (0.49) | PDPK1JAK2HTR2AFADS1METAP2 | |
| SCHEMBL786329 | 0.78 | JAK2 (1.00) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL4734012 | 0.77 | CSNK1D (0.71) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL182633 | 0.76 | JAK2 (0.63) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL2300691 | 0.76 | PDPK1 (0.63) | PDPK1JAK2DYRK1AFLT3CLK4 | |
| SCHEMBL2304825 | 0.76 | JAK2 (0.63) | PDPK1JAK2DYRK1AFLT3CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722209-A1 | PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Shenogen Pharma Group (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12240830-B2 | Fused ring heteroaryl compounds and use thereof | BISICHEM CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| WO-2024245169-A1 | PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京盛诺基医药科技股份有限公司 | 2024-12-05 | — | — | WO | disclosed |
| US-20240368132-A1 | ROCK2 INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2024-09-12 | — | — | US | disclosed |
| EP-4384511-A1 | FUSED RING HETEROARYL COMPOUNDS AND USE THEREOF | Bisichem Co., Ltd. (KR) | 2024-06-19 | — | — | EP | disclosed |
| EP-4377306-A1 | ROCK2 INHIBITORS AND USES THEREOF | President and Fellows of Harvard College (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-118055926-A | ROCK2 inhibitors and uses thereof | 哈佛大学的校长及成员们 | 2024-05-17 | — | — | CN | disclosed |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-4352049-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | Avelos Therapeutics Inc. (KR) | 2024-04-17 | — | — | EP | disclosed |
| WO-2012037410-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7812045-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-10-12 | — | — | US | disclosed |
| US-20080194661-A1 | Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368132-A1 | ROCK2 INHIBITORS AND USES THEREOF | ROCK2, ROCK1, RHOA | PDPK1 442/4885JAK2 217/4885DYRK1A 1976/4885 |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | DLD, GCDH, DLAT | PDPK1 1608/4885JAK2 4773/4885DYRK1A 4652/4885 |
| US-12240830-B2 | Fused ring heteroaryl compounds and use thereof | ALK, CYP3A5, SMAD3 | PDPK1 3128/4885JAK2 533/4885DYRK1A 1417/4885 |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | MAST1, MAST3, MAST4 | PDPK1 30/4885JAK2 452/4885DYRK1A 927/4885 |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | PDPK1 2379/4885JAK2 1663/4885DYRK1A 2928/4885 |
| US-20080194661-A1 | Antifungal Triazole Derivatives | ERG28, CYP51A1, CYP3A43 | PDPK1 1118/4885JAK2 1602/4885DYRK1A 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.